Mechanism of Action
Glucagon Receptor Signaling
Glucagon binds the glucagon receptor (GCGR), a Gs-coupled GPCR expressed most highly in the liver, kidney, and intestine. Receptor activation increases hepatic cAMP, activating PKA which phosphorylates glycogen phosphorylase (activating glycogenolysis) and phosphorylates PFK-2 (reducing glycolysis). PKA also activates CREB, driving expression of gluconeogenic enzymes including PEPCK and glucose-6-phosphatase.
Metabolic and Energetic Effects
Beyond glucose production, glucagon stimulates lipolysis in adipose tissue and hepatic fatty acid oxidation, raising circulating free fatty acids and ketone bodies during fasting. In brown adipose tissue, glucagon receptor activation promotes thermogenesis. Glucagon also reduces appetite through CNS GCGR signaling, an effect leveraged in GLP-1/glucagon dual agonist drug development.
Research Summary
Hypoglycemia Rescue
HumanGlucagon is the established emergency treatment for severe hypoglycemia in insulin-treated diabetes. Multiple delivery forms are FDA-approved including traditional lyophilized" class="wiki-gloss-link">lyophilized kits requiring reconstitution, liquid-stable preparations, and intranasal glucagon powder (Baqsimi) that achieves therapeutic blood glucose elevation without injection.
Obesity and Multi-Agonist Drug Development
HumanGlucagon receptor co-agonism combined with GLP-1 receptor agonism produces greater weight loss than GLP-1 alone in Phase II trials, attributed to increased energy expenditure and enhanced lipolysis. Retatrutide (GLP-1/GIP/glucagon triple agonist) showed up to 24% weight loss in Phase II trials, with glucagon receptor activity contributing through thermogenic and appetite-suppressing mechanisms.
Non-Alcoholic Fatty Liver Disease
HumanGlucagon receptor agonism reduces hepatic fat through direct stimulation of hepatic lipid oxidation and reduced lipogenesis. GCGR activation raises fibroblast-growth-factor-21/" class="wiki-internal-link">fgf-21/" class="wiki-internal-link">FGF-21 and reduces hepatic lipid accumulation. This provides mechanistic rationale for including glucagon receptor agonism in NASH drug development programs.
Calculate your Glucagon dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Hypoglycemia rescue | 1 mg | Single dose as needed | IM, SC, or intranasal |
| Metabolic/thermogenesis research | 50-200 mcg | Daily or infusion | Subcutaneous (research) |
Reconstituted glucagon must be used within 24 hours; it degrades rapidly in solution. For metabolic research, stable glucagon analogs with extended half-life are preferred.
Interactions
Safety Profile
Glucagon is a well-established therapeutic with decades of clinical safety data. Nausea, vomiting, and transient hyperglycemia are expected effects. Phlebitis can occur with repeated IV use. No significant long-term toxicity has been identified. Concerns with GCGR agonism for weight loss include potential effects on bone density and risk of hypoglycemia when combined with insulin, which are being monitored in ongoing trials.
References
- [1]Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol. 2003;284(4):E671-E678.
- [2]Day JW, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749-757.
- [3]Liskiewicz AD, et al. Intranasal glucagon rescue of hypoglycemia. Diabetes Care. 2019.